FDA Approves COMETRIQ™ (Cabozantinib) To Treat Medullary Thyroid Cancer
CAPRELSA(vandetanib) News — 2011
AstraZeneca has developed the “CAPRELSA Patient Access Services,” or CPAS to assess patients’ insurance coverage and direct patients to appropriate sources for financial assistance for which they may be eligible. The CPAS phone number is 800-367-4999. The CAPRELSA REMS program is at http://www.caprelsarems.com
FDA Approves Vandetanib on April 6, 2011
Letters to the FDA Support Vandetanib
ThyCa Participates at FDA Hearing on Vandetanib
Ball, M.D., To Speak on May 10, 2008, at Mid-Atlantic Thyroid
Cancer Survivorsí Workshop near Washington, DC.
thyroid cancer specialist Douglas Ball, M.D., Endocrinologist
at Johns Hopkins Hospital in Baltimore, Maryland, will speak
and answer questions about medullary thyroid cancer at the 7th
Annual Mid-Atlantic Thyroid Cancer Survivorsí Workshop.
workshop will take place in Falls Church, Virginia (near Washington,
DC) on Saturday, May 10, 2008. The event starts at 8 a.m. and
goes until 5 p.m.
thyroid surgeon and several other physicians will also speak
at this free one-day event. This workshop is open to anyone
interested in thyroid cancer.
I. Halzel, Pharm.D., Co-Moderator of the ThyCa Medullary Thyroid
Cancer E-Mail Group, will lead roundtable discussions for medullary
thyroid cancer survivors and caregivers.
room rates have been arranged at a hotel located near the workshop.
details about the speakers, schedule, hotel, and transportation
directions, visit ThyCa's Conferences
free workshop is one of several special events sponsored this
spring by the national nonprofit organization ThyCa: Thyroid
Cancer Survivorsí Association, Inc.. Throughout the year, ThyCa
also sponsors free local support groups, person-to-person support,
e-mail groups, a survivors' toll-free number, and many other
services and resources. Details are available on the ThyCa web
site or by calling toll-free 1-877-588-7904.